Business Wire

Samsung Bioepis' RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea

Del

Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® (infliximab), also known as SB2 – for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis and plaque psoriasis. This marks the second regulatory approval for Samsung Bioepis in Korea. The MFDS approved in September 2015 Samsung Bioepis’ BRENZYS®, a biosimilar version of Enbrel® (etanercept), also known as SB4.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151204005228/en/

Christopher Hansung Ko, President & CEO of Samsung Bioepis (Photo: Business Wire)

Christopher Hansung Ko, President & CEO of Samsung Bioepis (Photo: Business Wire)

“We look forward to the introduction of RENFLEXIS® in Korea, where patients suffering from autoimmune diseases will soon have access to an affordable, high-quality biologic treatment option,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “With an extensive pipeline of biosimilars on the way, we will continue to leverage our strengths in product development and quality assurance to bring these life-enhancing medications to patients who need them most.”

Samsung Bioepis is solely responsible for the development of all immunology and oncology biosimilars in its pipeline, including RENFLEXIS®, as well as global clinical trials and regulatory registration in all markets worldwide for these biosimilars. As according to the commercialization agreement signed in 2013 with Merck, MSD Korea will be responsible for the marketing, sales and distribution of RENFLEXIS® in Korea.

In a 54-week Phase 3 clinical study, RENFLEXIS® showed comparable safety and equivalent efficacy to Remicade®, as evidenced in ACR20 response rate of 65.3% in the RENFLEXIS® arm versus 69.2% in the Remicade® arm. The RENFLEXIS® study randomized 584 patients with moderate to severe rheumatoid arthritis despite methotrexate therapy across 73 sites in 11 countries.

In addition to RENFLEXIS®, Samsung Bioepis has been developing two other anti-tumor necrosis factor-alpha (anti-TNF-α) investigational biosimilar candidates, the latest developments for which are as follows:

  • SB4 investigational biosimilar candidate referencing Enbrel ® (etanercept): On November 9, 2015 at the Annual Meeting of the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) in San Francisco, Samsung Bioepis announced 52-week Phase 3 SB4 clinical study results that showed comparable safety and equivalent efficacy to Enbrel®, as evidenced in ACR20 response rate of 80.8% in the SB4 arm versus 81.5% in the Enbrel® arm. The SB4 study randomized 596 patients across 70 sites in 10 countries.

    In September 2015, Korea’s MFDS approved SB4, which will be commercialized by MSD Korea as BRENZYS®. In November 2015, the European Medicines Agency (EMA) announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on SB4, marking the first time the CHMP has adopted a positive opinion on an etanercept biosimilar. If a marketing authorization is granted by the European Commission (EC), SB4 will be commercialized in the European Union (EU) as Benepali®.
  • SB5 investigational biosimilar candidate referencing Humira ® (adalimumab): On November 10, 2015 at the ACR/ARHP Annual Meeting in San Francisco, Samsung Bioepis announced 24-week Phase 3 clinical study results that showed comparable safety and equivalent efficacy to Humira®, as evidenced in ACR20 response rate of 72.5% in the SB5 arm versus 72.0% in the Humira® arm. The study randomized 544 patients with moderate to severe rheumatoid arthritis despite methotrexate therapy across 52 sites in seven countries.


About Samsung Bioepis Co., Ltd.
Samsung Bioepis was established in 2012 with a mission to develop affordable, high-quality biopharmaceutical products and to provide better patient access to these life-enhancing medications. The company aims to be the world’s leading biopharmaceutical company through innovations in product development and quality assurance.

Samsung Bioepis has commercial agreements with Biogen and Merck to commercialize and distribute biosimilar products in immunology, oncology and diabetes. The products and geographic responsibilities include:

Biogen

  • SB4, investigational biosimilar candidate referencing Enbrel® (etanercept) – European Union, Switzerland, Japan
  • SB2, investigational biosimilar candidate referencing Remicade® (infliximab) – European Union, Switzerland, Russia, Turkey
  • SB5, investigational biosimilar candidate referencing Humira® (adalimumab) – European Union, Switzerland, Russia, Turkey

Merck

  • SB4, investigational biosimilar candidate referencing Enbrel® (etanercept) – Worldwide, but excluding United States, European Union, Switzerland, Japan
  • SB2, investigational biosimilar candidate referencing Remicade® (infliximab) – Worldwide, including United States, but excluding European Union, Switzerland, Russia, Turkey
  • SB5, investigational biosimilar candidate referencing Humira® (adalimumab) – Worldwide, including United States, but excluding European Union, Switzerland, Russia, Turkey
  • SB3, investigational biosimilar candidate referencing Herceptin® (trastuzumab) – Worldwide
  • SB9 (MK-1293), investigational biosimilar candidate referencing Lantus® (insulin glargine) – Worldwide

Samsung Bioepis is a joint venture between Samsung Biologics and Biogen. For more information, please visit: www.samsungbioepis.com.

Contact information

Samsung Bioepis Co., Ltd.
MEDIA CONTACT:
Mingi Hyun, +82-32-455-6128
mingi.hyun@samsung.com
INVESTOR CONTACT:
Kwang Ryu, +82-32-455-6149
kwang1.ryu@samsung.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Alps Electric to Exhibit at Major Chinese Trade Show ELEXCON 201714.12.2017 06:00Pressemelding

Japanese electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (President: Toshihiro Kuriyama; Head Office: Tokyo) will exhibit at ELEXCON 2017, to be held at the Shenzhen Convention & Exhibition Center in Shenzhen, China, from December 21. The company will introduce a wide range of technologies, particularly in the Internet of Things (IoT) domain. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213005033/en/ Alps Electric Booth Design (Graphic: Business Wire) At ELEXCON 2017, one of China’s largest electronics expositions, Alps Electric will showcase technologies and solutions targeting each of the Internet of Things (IoT), Mobile and Automotive markets. Exhibit Highlight: IoT Sensor Network Module A sensor module for collecting a variety of data,

Photo Press Release: Giant Gingerbread Burj Khalifa Unveiled at DXB14.12.2017 05:57Pressemelding

A 14 metre tall Burj Khalifa made of gingerbread takes centre stage at Dubai Airports’ Winter Wonderland DXB now open at Dubai International’s Terminal 3, B gates. “ Winter Wonderland DXB is the perfect way to get in the festive spirit just moments before jumping on a plane. An instagrammable village scene, set right in the middle of the airport, with entertainment for children and adults, visits from the main man in red on his sleigh and more!” said Helen Mellor-Mitchell, VP Media and Brand Engagement, Dubai Airports. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213006275/en/ Winter Wonderland DXB arrives at Dubai International Airport (Photo: AETOSWire) Editors Notes Dubai Airports manages the operation and development of both of

As Part of the Fourth Annual Forum for Promoting Peace in Muslim Societies14.12.2017 05:20Pressemelding

Undersecretary-General Adama Dieng, United Nations Special Adviser on the Prevention of Genocide, announced a joint cooperation agreement between the United Nations and the Forum for Promoting Peace in Muslim Societies to organize ten research workshops to promote religious education in the Islamic world. Dieng said the agreement was attained following a set of previous meetings with His Excellency Shaykh Abdallah bin Bayyah, President of the Forum for Promoting Peace in Muslim Societies. Both parties discussed a potential cooperation between them to promote religious education via extensive academic programs, and agreed to organize ten research workshops the details of which shall be announced later. Dieng explained that the United Nations highly appreciates the efforts exerted by the Forum for Promoting Peace in Muslim Societies to promote tolerance and coexistence among p

Global Game Exhibition 'G-STAR 2017' Ends with a Big Finale14.12.2017 00:00Pressemelding

The global game exhibition ‘G-STAR 2017’ had attendees in 2,857 booths from 676 companies in 35 countries and was the largest ever held in history; amidst an enthusiastic response from industries and attendees it ended with a big finale. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213005402/en/ G-STAR 2017 Public Area (Photo: Business Wire) ‘G-STAR 2017’ was hosted by the Korea Gaming Industry Association (K-GAMES) and managed by the G-STAR Organizing Committee and the Busan IT Industry Promotion Agency. It was held for four days from November 16 (Thursday) through November 19 (Sunday) at the Busan BEXCO. This was the 13th year for ‘G-STAR’, and it opened its doors to attendees with a variety of contents in an area approximately 55,300 square meters in size which included Exhib

IFF Declares Dividend for Fourth Quarter 201713.12.2017 21:15Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, announced that its Board of Directors has declared a regular quarterly cash dividend of $0.69 per share of the Company’s common stock, payable on January 8, 2018 to shareholders of record as of December 29, 2017. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers taste, smell, or feel in fine fragrances and beauty, detergents and household goods, as well as beloved foods and beverages. Our 7,400 team members globally take a

Limelight Networks Enhances DDoS Security Services with Faster Mitigation of Malicious Website Attacks13.12.2017 19:18Pressemelding

Limelight Networks, Inc. (Nasdaq: LLNW), a global leader in digital content delivery, today introduced new capabilities to its DDoS Attack Interceptor Service that provide high-capacity on-network scrubbing and a scalable range of protection measures for web infrastructure, with the ability to easily increase protection as security requirements change. Protecting websites from online attacks and cyber threats is one of the most pressing security challenges today. For example, data from Limelight’s State of Cybersecurity Report: SE Asia shows consumers are very concerned about the security of ecommerce sites, with 72 percent saying they have a negative opinion of a brand after hearing that it has suffered a cyberattack. In addition, 51 percent of online websites feel they are vulnerable to attacks that could have significant financial and b

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom